Miniatura

Fitxers

680095.pdf (5.35 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2017-05-02

Llicència de publicació

cc-by (c) Puente, Javier et al., 2017
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/178656

Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.18632/oncotarget.16494

Resum

Background: several potential predictive markers of efficacy of targeted agents in patients with metastatic renal cell carcinoma (mRCC) have been identified. Interindividual heterogeneity warrants further investigation. Patients and methods: multicenter, observational, retrospective study in patients with clear-cell mRCC treated with sunitinib. Patients were classified in two groups: long-term responders (LR) (progression-free survival (PFS)≥22 months and at least stable disease), and primary refractory (PR) (progressive disease within 3-months of sunitinib onset). Objectives were to compare baseline clinical factors in both populations and to correlate tumor expression of selected signaling pathways components with sunitinib PFS. Results: 123 patients were analyzed (97 LR, 26 PR). In the LR cohort, overall response rate was 79% and median duration of best response was 30 months. Median PFS and overall survival were 43.2 (95% confidence intervals[CI]:37.2-49.3) and 63.5 months (95%CI:55.1-71.9), respectively. At baseline PR patients had a significantly lower proportion of nephrectomies, higher lactate dehydrogenase and platelets levels, lower hemoglobin, shorter time to and higher presence of metastases, and increased Fuhrman grade. Higher levels of HEYL, HEY and HES1 were observed in LR, although only HEYL discriminated populations significantly (AUC[ROC]=0.704; cut-off=34.85). Increased levels of hsa-miR-27b, hsa-miR-23b and hsa-miR-628-5p were also associated with prolonged survival. No statistical significant associations between hsa-miR-23b or hsa-miR-27b and the expression of c-Met were found. Conclusions: certain mRCC patients treated with sunitinib achieve extremely long-term responses. Favorable baseline hematology values and longer time to metastasis may predict longer PFS. HEYL, hsa-miR-27b, hsa-miR-23b and hsa-miR-628-5p could be potentially used as biomarkers of sunitinib response.

Matèries

Marcadors bioquímics, Càncer de ronyó, Mortalitat

Matèries (anglès)

Biochemical markers, Renal cancer, Mortality

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

PUENTE, Javier, LAINEZ, Nuria, DUEÑAS, Marta, MÉNDEZ-VIDAL, María josé, ESTEBAN, Emilio, CASTELLANO, Daniel, MARTINEZ-FERNÁNDEZ, Mónica, BASTERRETXEA, Laura, JUAN FITA, María josé, ANTÓN, Luis, LEÓN, Luis, LAMBEA, Julio, PÉREZ-VALDERRAMA, Begoña, VÁZQUEZ, Sergio, SUAREZ, Cristina, GARCÍA DEL MURO SOLANS, Xavier, GALLARDO, Enrique, MAROTO, José pablo, SAMANIEGO, M. luz, SUÁREZ-PANIAGUA, Beatriz, SANZ, Julián, PARAMIO, Jesús m., SOGUG (Spanish Oncology Genitourinary Group). Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma. _Oncotarget_. 2017. Vol. 8, núm. 18, pàgs. 30410-30421. [consulta: 20 de gener de 2026]. ISSN: 1949-2553. [Disponible a: https://hdl.handle.net/2445/178656]

Exportar metadades

JSON - METS

Compartir registre